Answers are grounded in this paper and cite their sources.
National survey observes virological efficacy and resistance mutations in people with HIV-1, highlighting therapeutic outcomes of doravirine.
Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF.
No takes yet. Share an insight, caveat, or question.
Soulié et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: